Mirati Therapeutics Inc. (MRTX)

Oncology Corporate Profile

Stock Performance

4.9500
0.0500

HQ Location

9363 Towne Centre Drive, Suite 200
San Diego, CA 92121

Company Description

Mirati Therapeutics is a publicly-traded biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Our compounds result from internal chemistry efforts targeting the active sites of enzymes that are key drivers of tumor growth. Our clinical development programs are focused on treating selected tumor types that express high levels of these targets in order to most effectively address unmet patient needs. Our lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. We are also evaluating development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor and MGCD516, a kinase inhibitor with a distinct target profile.

Website: http://www.mirati.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
mocetinostatHDAC inhibitorBladder cancerII
mocetinostatHDAC inhibitorDiffuse large B-cell Lymphoma (DLBCL)II
mocetinostatHDAC inhibitorMyelodysplastic Syndrome (MDS)II
MGCD265multiple tyrosine kinase inhibitorHead & Neck cancerI
MGCD265multiple tyrosine kinase inhibitorNon Small Cell Lung Cancer (NSCLC)I
MGCD516multiple tyrosine kinase inhibitorVarious cancer typesI
mocetinostat (+ MEDI4736)HDAC inhibitorVarious cancer typesIMedimmune

View additional information on product candidates here »

Source: http://www.mirati.com

Recent News Headlines

7/24/2017 06:19 pm

7/24/2017 06:19 pm

7/24/2017 06:19 pm

7/24/2017 06:19 pm

7/18/2017 06:19 am

7/18/2017 06:19 am

7/18/2017 06:19 am

7/18/2017 06:19 am

7/5/2017 12:20 pm

7/5/2017 12:20 pm

7/5/2017 12:20 pm

7/5/2017 12:20 pm

6/27/2017 12:19 pm

6/27/2017 12:19 pm

6/27/2017 12:19 pm

6/27/2017 12:19 pm

5/31/2017 12:19 pm

5/4/2017 12:18 pm

Mirati reports 4Q loss

3/9/2017 11:04 pm

Mirati reports 4Q loss

3/9/2017 11:04 pm

Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016

3/9/2017 09:00 pm

[PR Newswire] - SAN DIEGO, March 9, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) ("the Company," "we," "our," "us," or "Mirati") today reported financial ...

Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference

2/13/2017 09:00 pm

[PR Newswire] - SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D, Ph.D., President and CEO of Mirati, will provide a corporate overview during ...